Polysaccharides (e.g., Cellulose, Etc.) Patents (Class 424/488)
  • Patent number: 10369118
    Abstract: A method for reducing scarring comprises applying into a wound a composition comprising resveratrol. The wound was formed at most one day before the applying, and no part of the skin surface of the wound is more than 3 cm from uninjured skin.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: August 6, 2019
    Assignee: Cole Research & Design, LLC
    Inventor: Jeptha N. Cole
  • Patent number: 10342882
    Abstract: The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: July 9, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Jose Manuel Mejia Oneto, Maksim Royzen
  • Patent number: 10328096
    Abstract: Composition comprising chitosan for use in the prevention and/or treatment of incontinence and/or impotence in a subject undergoing prostatectomy.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: June 25, 2019
    Assignees: UNIVERSITA' DEGLI STUDI DI TORINO
    Inventors: Thomas Freier, Stefano Geuna, Francesco Porpiglia
  • Patent number: 10293079
    Abstract: This invention provides a kit for making an adhesive and/or a sealant which includes: a first composition of alginate and a multivalent cation salt at a concentration ratio (mg/ml) of 30:1 to 1:60, and a second composition of alginate and a buffer, wherein the buffer has a pH value of between 2 to 7. The invention also provides a method for making a sealant or an adhesive, by contacting the first composition and the second composition.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: May 21, 2019
    Assignee: SEALANTIS LTD.
    Inventors: Ohad Kimhi, Ronit Langzam-Sinai, Havazelet Bianco-Peled, Charles Milgrom, Rina Lev
  • Patent number: 10272156
    Abstract: A liquid composition which comprises an organic liquid diluent and at least one non-ionic cellulose ether having a viscosity of up to 2.33 mPa·s, measured as a 2 wt.-% solution in water at 20° C., is stable over an extended time period. The liquid composition is useful for preparing a solid dispersion comprising at least one active ingredient in at least one cellulose ether by spray-drying. Alternatively a solid dispersion can be produced by blending and extruding at least one active ingredient, at least one cellulose ether having a viscosity of up to 2.33 mPa·s and optionally one or more adjuvants.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: April 30, 2019
    Assignee: DOW GLOBAL TECHNOLOGIES LLC
    Inventors: Meinolf Brackhagen, Nicholas S. Grasman, Mark J. Hall, Steven J. Guillaudeu, Robert L. Schmitt, Matthias Knarr
  • Patent number: 10232087
    Abstract: A porous matrix suitable for use as a tissue scaffold is described. The matrix may be shaped before insertion into or at the target tissue site, or injected via a minimally invasive method. The matrix may be pre-seeded with cells of the target tissue or may be used to support growth of the local endogenous tissue. The matrix may contain growth factors or other pharmacologically acceptable moieties such as antibiotics.
    Type: Grant
    Filed: March 29, 2004
    Date of Patent: March 19, 2019
    Assignee: LOCATE THERAPEUTICS LIMITED
    Inventors: Richard Melville France, Robin Andrew Quirk
  • Patent number: 10220047
    Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: March 5, 2019
    Assignee: OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: P. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stephen A. Strugnell
  • Patent number: 10208403
    Abstract: A viscose fiber comprises a fiber body including a regenerated cellulosic material and a plurality of microcapsules dispersed in the regenerated cellulosic material. The regenerated cellulosic material is derived from an organic plant material and the plurality of microcapsules containing a phase change material has a transition temperature in the range of 0° C. to 100° C., the phase change material providing thermal regulation based on at least one of absorption and release of latent heat at the transition temperature.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: February 19, 2019
    Assignee: OUTLAST TECHNOLOGIES, LLC
    Inventors: Mark Hartmann, James Brice Worley, Matthew North
  • Patent number: 10201576
    Abstract: The present invention discloses a herbal formulation comprising therapeutic effective amount of plant extract of Woodfordia Floribunda; therapeutic effective amount of plant extract of Centella Asiatica; and an effective amount of at least one pharmaceutically acceptable excipient.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: February 12, 2019
    Assignee: Ultratech India Limited
    Inventor: Bhatia Rishi
  • Patent number: 10195252
    Abstract: The present invention provides microparticles that deliver in vivo predictable release profiles of at least one chemokine to create a biomimetic chemokine concentration gradient that induces the migration of multipotent stem cells to the anatomical site of the microparticles. Various release profiles are demonstrated that depend upon the relative concentration of alginate in the chemokine-loaded microparticle. Local administration and/or intraarticular injection of the microparticles are useful in conditions such as osteoarthritis. Targeted systemic delivery of the alginate chemokine microparticles to distant anatomical sites subjected to autoimmune disease symptomology can be performed by encapsulation within liposomes having targeting ligands. Consequently, upon the creation of the appropriate chemokine gradient, multipotent stem cells will migrate to the distant anatomical site where the liposomes are attached.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: February 5, 2019
    Assignee: University Of Pittsburgh—Of The Commonwealth System of Higher Education
    Inventors: Steven R. Little, Riccardo Gottardi, Mintai Peter Hwang, Daniel DeSantis
  • Patent number: 10179779
    Abstract: The present invention relates to novel crystal forms of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid. More particularly, the invention relates to polymorph forms of Polymorph Form I, Polymorph Form II, Polymorph Form III, Polymorph Form IV, Polymorph Form V, and Polymorph Form VI, and to processes for the preparation of, compositions containing and to uses of, such polymorph forms.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: January 15, 2019
    Assignee: RaQualia Pharma Inc.
    Inventors: Toyoharu Numata, Hideyuki Aoyama, Kaori Muraji
  • Patent number: 10172954
    Abstract: The present invention relates to reverse-micellar systems comprising at least an active agent, an acylglycerol, a sterol, lecithin, ethanol and water, for use in chelation and/or sequestering of a radionuclide and/or a metal in a patient. The invention also relates to the reverse-micellar systems and to pharmaceutical compositions comprising said reverse-micellar systems.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: January 8, 2019
    Assignee: MEDESIS PHARMA
    Inventors: Caroline Bauer, Elsa Compte, Olivier Gremy, Laurent Miccoli, Jaime Francisco Angulo-Mora, Jean-Claude Maurel
  • Patent number: 10154976
    Abstract: The disclosed invention provides a system and method of artificially retarding fibrin-based blood clot degradation via the sustained release of a protease inhibitor, such as, for example, aprotinin or tranexamic acid (“TA”). The sustained release of the protease inhibitor is accomplished through incorporation within a biodegradable polymer microsphere to produce a protease inhibitor formulation. Next, the formulation along with fibrinogen and thrombin is applied to a wound site where an outer surface of the polymer microsphere degrades in a proteolytic environment to expose and release the incorporated protease inhibitor to the surrounding hydrogel or sealant or clot matrix at the wound site.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: December 18, 2018
    Assignee: Bordoloi Biotech, LLC
    Inventors: Binoy K Bordoloi, Nayan J Sarma, Rodney L. Eisenberg
  • Patent number: 10155824
    Abstract: A method of producing a carboxymethyl-group-containing modified hyaluronic acid and/or a salt thereof includes a step of subjecting, in a water-containing solvent having a temperature of 30° C. or less, a dissolved raw material hyaluronic acid and/or a salt thereof to a reaction with a haloacetic acid and/or a salt thereof, the water-containing solvent including water or a liquid mixture of a water-soluble organic solvent and water, a ratio of the water-soluble organic solvent in the liquid mixture being 60 v/v % or less.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: December 18, 2018
    Assignee: KEWPIE CORPORATION
    Inventors: Shunichi Fujikawa, Yukina Abe, Kazunori Asaoka, Takushi Yoshida
  • Patent number: 10154881
    Abstract: Disclosed herein are methods of connecting disrupted tissue, tissue repair, treating colorectal disorder and tissue welding. The methods comprise using a bioadhesive composition comprising ELP and light absorbing chromophores and irradiating the bioadhesive tissue.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: December 18, 2018
    Assignee: Arizona Board of Regents for and on behalf of Arizona State University
    Inventors: Kaushal Rege, Huang-Chiao Huang
  • Patent number: 10130584
    Abstract: The purpose of the present invention is to provide a new disintegrative particulate composition having an optimal balance between the tablet hardness and disintegrability that are mutually opposing properties, and disintegrating tablets for pharmaceuticals and various kinds of foods comprising said composition. The present invention relates to a disintegrative particulate composition comprising milled lactose and/or granulated lactose as an excipient, and to a disintegrating tablet for pharmaceuticals or foods, comprising the disintegrative particulate composition, especially the tablet having tablet hardness of from 20 to 200 N, and disintegration time in water of from 1 to 60 sec.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: November 20, 2018
    Assignee: DAICEL CORPORATION
    Inventors: Takahiro Hiramura, Kiyoshi Ikura, Tomohito Okabayashi, Yoshihisa Takigawa, Naohiro Hashikawa
  • Patent number: 10130711
    Abstract: The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: November 20, 2018
    Assignees: The Regents of the University of California, Alchemical Research Holdings, LLC
    Inventors: Jose Manuel Mejia Oneto, Ziyad F. Al-Rashid
  • Patent number: 10111838
    Abstract: A pharmaceutical or nutraceutical composition, contains a) a core a), containing a pharmaceutical or a nutraceutical active ingredient and b) a coating layer b), containing a mixture of 80 to 96% by weight of a water-insoluble (meth)acrylate polymer and 4 to 20% by weight of guar gum, wherein the water-insoluble (meth)acrylate polymer contains polymerized units of more than 95 and up to 100% by weight C1-C4-alkyl esters of acrylic acid or of methacrylic acid and less than 5% by weight of acrylic acid or methacrylic acid.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: October 30, 2018
    Assignee: Evonik Roehm GmbH
    Inventors: Shraddha Joshi, Ashish Guha, Vinay Jain
  • Patent number: 10104888
    Abstract: The invention provides a composition comprising a matrix of chitosan and a tannin wherein the chitosan is electrostatically bonded to the tannin to form a chitosan-tannin composite material. The chitosan can be partially or fully deacetylated, and the tannin can be a monomeric or an oligomeric proanthocyanidin or a hydrolysable tannin. The chitosan-tannin composite material can be a nanoparticle, a hydrogel film, a bio-foam, or a biogel, or the chitosan-tannin composite material can coat a liposome. The composite materials can be used for drug delivery, for antibacterial and/or antifungal applications, for tissue engineering applications, for wound healing applications, or they can be used as adjuvants for vaccination, including oral vaccinations. The invention also provides methods of preparing the composite materials and their various forms.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: October 23, 2018
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Jess Dreher Reed, Christian Gerald Krueger, Sergio Madrigal-Carballo
  • Patent number: 10093674
    Abstract: Disclosed are nucleopeptide compounds that include a nucleobase, and an amino acid. Certain compounds further comprise a glycoside. The compounds may self-assemble to form supramolecular hydrogels. Also, the compounds may be used as a platform to examine specific biological functions (e.g., binding to DNA and RNA) of a dynamic supramolecular system that is able to interact with both proteins and nucleic acids. Other uses include: methods of growing cells and methods of delivering a substance to a cell.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: October 9, 2018
    Assignee: Brandeis University
    Inventor: Bing Xu
  • Patent number: 10086113
    Abstract: A porous matrix suitable for use as a tissue scaffold is described. The matrix may be shaped before insertion into or at the target tissue site, or injected via a minimally invasive method. The matrix may be pre-seeded with cells of the target tissue or may be used to support growth of the local endogenous tissue. The matrix may contain growth factors or other pharmacologically acceptable moieties such as antibiotics.
    Type: Grant
    Filed: March 29, 2004
    Date of Patent: October 2, 2018
    Assignee: LOCATE THERAPEUTICS LIMITED
    Inventors: Richard Melville France, Robin Andrew Quirk
  • Patent number: 10080715
    Abstract: The invention relates to a process for preparing polysaccharide-based microparticles with improved mechanical properties and hydrolytic stability. The spherical particles are useful as exfoliating agents in cosmetic formulations, in replacement of the newly banned plastic microbeads. The method comprises the preparation of hydrogel particles, drying of the particles, and a solid-state reaction that results in the covalent stabilization of the material. The invention also encompasses microparticles made using the method.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: September 25, 2018
    Assignee: Bowling Green State University
    Inventors: Giuseppe Giammanco, Alexis Ostrowski
  • Patent number: 10052313
    Abstract: The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine and a polyol. The compositions optionally contain a cycloplegic agent, a surfactant, a viscosity enhancer, an osmolarity modifier and a preservative.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: August 21, 2018
    Assignee: PRESBYOPIA THERAPIES, LLC
    Inventors: Gerald Horn, Lee Nordan
  • Patent number: 9950002
    Abstract: A nanotheranostic probe and its use to facilitate diagnoses, treatment and targeting of amyloid deposits are disclosed herein.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: April 24, 2018
    Assignee: Regents of the University of Minnesota
    Inventor: Karunya K. Kandimalla
  • Patent number: 9926385
    Abstract: Provided are a method for producing a water-soluble cellulose ether having a low degree of polymerization and enhanced whiteness, and the like. The method includes the steps of: bringing a pulp powder having a multiplication product of less than 0.004 mm2 which is obtained by multiplying a number-average fiber length by a number-average fiber width, each measured with a Kajaani fiber length analyzer, into contact with an alkali metal hydroxide to obtain an alkali cellulose; reacting the alkali cellulose with an etherifying agent to obtain a crude water-soluble cellulose ether having a high degree of polymerization; purifying the crude water-soluble cellulose ether; drying the purified water-soluble cellulose ether; grinding the dried water-soluble cellulose ether into a water-soluble cellulose ether powder; and depolymerizing the water-soluble cellulose ether powder to obtain the water-soluble cellulose ether having a low degree of polymerization.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: March 27, 2018
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventors: Akira Kitamura, Mitsuo Narita, Takuya Yokosawa, Yuichi Nishiyama
  • Patent number: 9896572
    Abstract: The invention provides a coffee pulp treatment process comprising (a) Providing coffee pulp, obtainable from a production process for producing green coffee beans from coffee cherries; (b) extracting from the coffee pulp a pectin comprising extract, wherein extraction is performed under acid conditions or alkaline conditions, to provide the pectin comprising extract; (c) enzymatic treatment of the pectin comprising extract, wherein the enzymatic treatment comprises a treatment with one or more enzymes selected from the group consisting of an esterase and a reductase, to provide a enzymatically treated pectin material; and (d) extraction of polyphenol functionalized coffee pectin extract from the enzymatically treated pectin material.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: February 20, 2018
    Assignee: Pectcof B.V.
    Inventor: Andres Felipe Belalcazar Otalora
  • Patent number: 9855206
    Abstract: Provided is hyaluronic acid gel suitable for cosmetic and medical field. The hyaluronic acid gel contains hyaluronic acid, polycarboxylic acid or oxycarbonic acid, and polyhydric alcohol. The hyaluronic acid gel is produced by drying moisture of an aqueous solution in which the hyaluronic acid, the polycarboxylic acid, and the polyhydric alcohol are uniformly dissolved to be an intended form.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: January 2, 2018
    Assignee: COSMED PHARMACEUTICAL CO., LTD.
    Inventors: Kunio Yoneto, Junya Hasegawa, Naoko Kondou, Ying-shu Quan, Fumio Kamiyama
  • Patent number: 9782365
    Abstract: The present invention relates to solid preparations containing ambroxol which are obtainable by melt extrusion of the mixture consisting of a) 30 to 80% by weight of ambroxol hydrochloride, b) 2 to 68% by weight of at least one hydrogenated vegetable oil, c) 2 to 68% by weight of at least one mixture containing fatty acid ester and/or hydroxy fatty acid ester and d) 0 to 66% by weight of one or more pharmaceutical adjuvants, based in each case on the total amount of the preparation and its use for secretolytic treatment in acute and chronic bronchopulmonary diseases.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: October 10, 2017
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Rolf-Stefan Brickl, Herrad-Odilia Krenkel
  • Patent number: 9775931
    Abstract: The invention relates to methods of preparing a bone matrix solution, a bone matrix implant, and variants thereof. The invention also relates to methods of cell culture using the same. The invention further relates to bone matrix scaffolds comprising one or more bone matrix nanofibers, methods of preparing, and methods of use thereof. The invention also relates to methods of culturing cells and promoting differentiation of stem cells using the same.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: October 3, 2017
    Assignee: LifeNet Health
    Inventors: Michael Francis, Roy Ogle
  • Patent number: 9771668
    Abstract: A fluid-swellable fiber in particular for the use as a surgical suture, the fiber comprising chitosan, the fiber's swelling ratio being less than 100%, and a fabric comprising the fiber. Moreover, a method of manufacturing from a chitosan-containing solution a fiber comprising chitosan, wherein during manufacture, the solution is brought into contact with a coagulation medium containing at least one organic solvent, a method of removing a fiber from a living organism, wherein the fiber is at least partly dissolved in a solvent applied from the outside, and a kit comprising a chitosan containing fiber and a solvent for at least partly dissolving the fiber.
    Type: Grant
    Filed: February 2, 2010
    Date of Patent: September 26, 2017
    Assignee: Medovent GmbH
    Inventors: Rivelino Montenegro, Thomas Freier
  • Patent number: 9763464
    Abstract: The invention is directed to a potassium containing preparation or potassium bolus for the prevention or treatment of potassium deficit and optionally other deficit of minerals in ruminants, a process for the production thereof as well as the use thereof. The present invention makes it possible to provide a potassium containing preparation or potassium bolus with a high content of up to 70 wt.-% of potassium salt, based on the total weight of the potassium containing preparation, by adding only a relatively small amount of calcium chloride (15 to 40 wt.-%) and water (10 to 22 wt.-%) to the potassium salt.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: September 19, 2017
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventor: Leif Hoejvang-Nielsen
  • Patent number: 9757499
    Abstract: Biofunctional films and methods of use thereof for the prevention of post-operative adhesions are disclosed.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: September 12, 2017
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Noshir Langrana, Devendra Verma, Michelle Previtera
  • Patent number: 9731019
    Abstract: The object of the present invention is novel release systems comprising specific hyaluronic acid amides combined with therapeutically and/or biologically active proteins with a mainly hydrophobic nature, for sustained, slow release over time which increases the efficacy of the medicament and the patient's compliance.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: August 15, 2017
    Assignee: FIDIA FARMACEUTICI S.P.A.
    Inventors: Monica Campisi, Cristian Guarise, Davide Renier
  • Patent number: 9731018
    Abstract: The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises both the polysaccharides levan and inulin.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: August 15, 2017
    Assignee: Ferring B.V.
    Inventors: Varinder Ahuja, Tejas Gunjikar, Balachendar Gundu
  • Patent number: 9675547
    Abstract: A dysphagia improving composition characterized in that a substance having an inhibitory action on an angiotensin converting enzyme, which is a degrading enzyme of substance P, is administered locally in a dosage not influencing blood pressure, and a pharmaceutical for improving dysphagia containing the composition.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: June 13, 2017
    Assignee: Meiji Seika Pharma Co., Ltd.
    Inventors: Koichi Kitamura, Maho Kondo, Kiyoshi Shimoyama, Toru Kurosawa
  • Patent number: 9675728
    Abstract: A wound dressing composition comprising a chitosan and an oxidized cellulose. For example, the composition may be in the form of a sponge formed by freeze drying an aqueous dispersion of chitosan and oxidized regenerated cellulose (ORC). The composition is especially suitable for the treatment of chronic wounds.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: June 13, 2017
    Assignee: KCI USA, Inc.
    Inventors: Breda Mary Cullen, Derek Walter Silcock
  • Patent number: 9668979
    Abstract: The present invention provides a microcapsule pharmaceutical composition of at least a bisquinoline drug. said microcapsule comprises a drug core of a pharmaceutically effective amount of a bisquinoline drug and a polymeric coating over the core. This microcapsule pharmaceutical composition has desirable pharmaceutical properties, including taste masking effect and a high stability.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: June 6, 2017
    Assignee: Adare Pharmaceuticals, Inc.
    Inventors: Christian Stollberg, Giancarla Bianchi, Flavio Fabiani, Luigi Boltri
  • Patent number: 9637470
    Abstract: Treatments are described for stress disorders and substance use disorders, for example, substance use disorders associated with use of alcohol, cocaine, amphetamines, and the like.
    Type: Grant
    Filed: February 22, 2014
    Date of Patent: May 2, 2017
    Inventors: Thomas F. Newton, Colin N. Haile
  • Patent number: 9611312
    Abstract: Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: April 4, 2017
    Assignee: ELASTAGEN PTY. LIMITED
    Inventor: Jens Sommer-Knudsen
  • Patent number: 9597303
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzine derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: March 21, 2017
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Patent number: 9545423
    Abstract: The invention provides a composition comprising a matrix of chitosan and a tannin wherein the chitosan is electrostatically bonded to the tannin to form a chitosan-tannin composite material. The chitosan can be partially or fully deacetylated, and the tannin can be a monomeric or an oligomeric proanthocyanidin or a hydrolysable tannin. The chitosan-tannin composite material can be a nanoparticle, a hydrogel film, a bio-foam, or a biogel, or the chitosan-tannin composite material can coat a liposome. The composite materials can be used for drug delivery, for antibacterial and/or antifungal applications, for tissue engineering applications, for wound healing applications, or they can be used as adjuvants for vaccination, including oral vaccinations. The invention also provides methods of preparing the composite materials and their various forms.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: January 17, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Jess Dreher Reed, Christian Gerald Krueger, Sergio Madrigal-Carballo
  • Patent number: 9539215
    Abstract: A method for preparing hydro/organo gelators from disaccharide sugars by biocatalysis and their use in enzyme-triggered drug delivery. Controlled delivery of an anti-inflammatory, chemopreventive drug is achieved by an enzyme-triggered drug release mechanism via degradation of encapsulated hydrogels. The hydro- and organo-gelators are synthesized in high yields from renewable resources by using a regioselective enzyme catalysis and a known chemopreventive and anti-inflammatory drug, curcumin, is encapsulated in the gel matrix and released by enzyme triggered delivery. The release of the drug occurs at the physiological temperature and control of the drug release rate is achieved by manipulating the enzyme concentration and temperature. The by-products formed after the gel degradation clearly demonstrated the site specificity of degradation of the gelator by enzyme catalysis.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: January 10, 2017
    Assignee: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK
    Inventors: George John, Praveen Vemula
  • Patent number: 9512495
    Abstract: Processes for converting lignocellulose to feedstock and downstream products are disclosed. The processes may include acid treatment of lignocellulose to produce a fermentation feedstock. In various instances, the processes include recovery or recycling of acid, such as recovery of hydrochloric acid from concentrated and/or dilute streams. Downstream products may include acrylic acid-based products such as diapers, paper and paper-based products, ethanol, biofuels such as biodiesel and fuel additives, and detergents.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: December 6, 2016
    Assignee: Virdia, Inc.
    Inventors: Aharon Eyal, Robert P. Jansen
  • Patent number: 9511021
    Abstract: The invention relates to certain nicotine chewing gums that provide for a high rate of buccal absorption and high plasma concentrations, in particular over the first 10 minutes after administration, in a subject willing to quit smoking.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: December 6, 2016
    Assignee: Novartis, A.G.
    Inventors: Markus Rudolph, Giovanna Marzano, Isabelle Rault
  • Patent number: 9493636
    Abstract: The present invention provides a method for preparing a water insoluble gel composition comprising: mixing a water soluble polysaccharide, an epoxy cross-linking agent, an alkaline compound and a solvent; and drying the thus obtained mixture at 1 to 30° C. under vacuum to remove the solvent, and a water insoluble gel composition.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: November 15, 2016
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Young Chang Ah, Sung Yeon Cho, In Seok Hwang, Sun Young Park, Hyun Ju Ko, Hyuk Kim, Min Jung Kwon, Won Seok Park
  • Patent number: 9492383
    Abstract: The present application provides rapid-gelling, sprayable hyaluronic-acid based compositions, kits, related methods, precursor formulations, and uses thereof.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: November 15, 2016
    Assignee: Carbylan Therapeutics, Inc.
    Inventors: David M. Gravett, George Y. Daniloff, Pingren He
  • Patent number: 9474721
    Abstract: The disclosure relates to a sustained-release oral dosage form for once-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydromorphone. The dosage form can have a release profile such that 16 hours following administration, less than about 85 percent of the hydromorphone is released. In addition, the dosage form may have alcohol and/or crush resistance.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: October 25, 2016
    Assignee: Cima Labs Inc.
    Inventors: Ehab Hamed, Manuel A. Vega Zepeda
  • Patent number: 9476087
    Abstract: The present invention relates to compounds for and a method of detecting beta-lactamase activity in a sample. The sample is contacted with a nanoparticulate tag. The nanoparticulate tag comprises a metal or a combination of metals, or it comprises a nanotube of a metal, boron nitride and/or carbon. The respective metal is capable of forming one of a covalent bond, a coordinative bond and a non-covalent interaction with a thio or a seleno group. The sample is contacted with a compound of one of general formulas (I)-(III) and (VII)-(IX). At least one beta-lactam moiety of the compound is cleaved by the beta-lactamase activity in the sample. As a result a cleavage moiety Z-A-Z, Z-A-Z—R15, Z-A-Z—R16, Z-A-Z—R17, Z-A-Z—R18 or Z-G-N(R8)R9 is released that is immobilized on the surface of the nanoparticulate tag by a covalent bond via a Z atom. The presence of beta-lactamase activity is determined based on the presence of the cleavage moiety immobilized onto the surface of the nanoparticulate tag.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: October 25, 2016
    Assignee: NANYANG TECHNOLOGICAL UNIVERSITY
    Inventors: Bengang Xing, Xianfeng Huang, Tingting Jiang, Rongrong Liu
  • Patent number: 9469802
    Abstract: The current invention relates to the use of chitin nanocrystals and chitin nanocrystal derivatives. More specifically, the present invention relates to the use of chitin nanocrystals and chitin nanocrystals used in oil and gas operations. The chitin nanocrystals and chitin nanocrystals derivatives can be used as additives to cement and wellbore fluids and can be used to inhibit corrosion in pipelines, on downhole tools and on other oil and gas related equipment.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: October 18, 2016
    Assignee: Halliburton Energy Services, Inc.
    Inventor: Lee Jeremy Hall
  • Patent number: 9421198
    Abstract: Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: August 23, 2016
    Assignee: TEOXANE
    Inventors: Francois Bourdon, Stephane Meunier